Hardman & Co: Shield Therapeutics' Focus on Cash Management

Shield Therapeutics, a commercial-stage pharmaceutical company, is focusing on delivering specialty products for unmet medical needs, primarily iron deficiency. Since launching in the US in July 2021, Shield and partner Viatris have increased physician awareness of Accrufer®, an oral iron deficiency drug. This effort is aimed at boosting prescriptions and generating sales momentum.

Positive trends in prescriptions recorded in 2022 and 2023 are anticipated to gain speed in 2024 and 2025. The company now aims to become cashflow positive by the second half of 2025. Enhanced financing options have also eliminated the need for a capital increase.